Incyte Corporation $INCY
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS36
PHASE 3 / 2-322
RECRUITING15
READOUTS ≤12 MONTHS12
READOUT SLIPPED >6 MO27%
Delay Index: of 30 active trials registered more than a year ago, 8 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Incyte Corporation on the live radar map → 📅 $INCY readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| InMIND NCT04680052 |
P3 | Active, not recruiting | Follicular Lymphoma; Marginal Zone Lymphoma | 654 | 2024-02-23 (+8 mo) |
| MINDway NCT05222555 |
P1/2 | Active, not recruiting | Diffuse Large B Cell Lymphoma | 53 | 2024-07-17 (+2 mo) |
| Povorcitinib NCT06113445 |
P3 | Active, not recruiting | NonSegmental Vitiligo | 467 | 2026-02-24 (-2 mo) |
| Povorcitinib NCT06113471 |
P3 | Active, not recruiting | NonSegmental Vitiligo | 450 | 2026-03-17 (-2 mo) |
| firmMIND NCT05429268 |
P3 | Active, not recruiting | Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma | 82 | 2026-03-30 (-9 mo) |
| TRuE-AD5 NCT06832618 |
P3 | Active, not recruiting | Atopic Dermatitis | 159 | 2026-08-07 |
| frontMIND NCT04824092 |
P3 | Active, not recruiting | Diffuse Large B-cell Lymphoma | 899 | 2026-09-01 (+15 mo) |
| Povorcitinib NCT06516965 |
P3 | Active, not recruiting | Prurigo Nodularis | 346 | 2026-09-28 |
| Axatilimab NCT06388564 |
P2 | Active, not recruiting | Chronic Graft-versus-host-disease | 130 | 2026-10-01 (-5 mo) |
| Ruxolitinib Cream NCT06958211 |
P3 | Active, not recruiting | Hidradenitis Suppurativa | 573 | 2026-10-01 |
| Povorcitinib NCT06516952 |
P3 | Active, not recruiting | Prurigo Nodularis | 349 | 2026-10-19 |
| Ruxolitinib Cream NCT06959225 |
P3 | Active, not recruiting | Hidradenitis Suppurativa | 580 | 2026-10-29 |
| Parsaclisib NCT04509700 |
P2 | Active, not recruiting | B-Cell Malignancies | 112 | 2026-11-05 (+17 mo) |
| povorcitinib NCT05851443 |
P2 | Active, not recruiting | Moderate to Severe Asthma | 247 | 2026-11-20 (+16 mo) |
| STOP-HS LTE NCT06212999 |
P3 | Active, not recruiting | Hidradenitis Suppurativa (HS) | 617 | 2026-12-26 |
| INCA034176 NCT06843408 |
P1/2 | Active, not recruiting | Chronic Graft-versus-host-disease | 32 | 2027-01-06 (+6 mo) |
| MAESTRA 1 NCT07023627 |
P2 | Recruiting | Ovarian Cancer | 160 | 2027-04-27 |
| Ruxolitinib Cream NCT06804811 |
P3 | Recruiting | NonSegmental Vitiligo | 250 | 2027-04-30 |
| Progress NCT05090891 |
P2 | Recruiting | Fibrodysplasia Ossificans Progressiva (FOP) | 98 | 2027-07-30 (+45 mo) |
| Tafasitamab NCT06465433 |
P2 | Recruiting | Hematologic Malignancies | 25 | 2027-08-29 |
| INCA000585 NCT07104565 |
P2 | Recruiting | Immune Thrombocytopenia | 56 | 2027-09-23 |
| AXemplify-357 NCT06585774 |
P3 | Recruiting | Chronic Graft-versus-host-disease | 240 | 2027-09-28 |
| Ruxolitinib NCT02955940 |
P2 | Active, not recruiting | Pancreatic Cancer; Colorectal Cancer (CRC) | 10 | 2027-09-30 (+107 mo) |
| MAESTRA 2 NCT07214779 |
P3 | Active, not recruiting | Ovarian Cancer | 13 | 2027-10-12 (-13 mo) |
| STOP-LTR NCT06855498 |
P3 | Recruiting | Hidradenitis Suppurativa (HS) | 600 | 2028-02-28 |
| Povorcitinib NCT07213973 |
P2 | Recruiting | Hidradenitis Suppurativa (HS) | 40 | 2028-03-25 |
| INCA034176 NCT06821542 |
P3 | Active, not recruiting | Chronic Graft-versus-host-disease | 9 | 2028-05-31 |
| TRuE-VIP1 NCT06548360 |
P3 | Recruiting | NonSegmental Vitiligo | 180 | 2028-06-05 (+22 mo) |
| DAWN-303 NCT07522073 |
P3 | Recruiting | Solid Tumors | 588 | 2028-09-15 |
| INCA33890 NCT07284849 |
P3 | Recruiting | CRC (Colorectal Cancer) | 700 | 2028-12-29 |
| INCA034176 NCT07124078 |
P2 | Recruiting | Chronic Graft-versus-host-disease | 60 | 2029-01-31 |
| NEXERA-204 NCT07823322 |
P2 | Recruiting | CRC (Colorectal Cancer) | 40 | 2029-05-14 |
| EXCALIBUR-ET2 NCT07623200 |
P3 | Recruiting | Essential Thrombocythemia | 426 | 2029-06-15 |
| Tacrolimus (Tac) NCT06615050 |
P3 | Recruiting | Graft-versus-host Disease (GVHD) | 572 | 2031-01-17 (+3 mo) |
| FIGHT-214 NCT07862998 |
P2 | Not yet recruiting | Unresectable Cholangiocarcinoma; Advanced/Metastatic Cholangiocarcinoma | 72 | 2031-02-25 |
| MAESTRA 3 NCT07797283 |
P3 | Not yet recruiting | Ovarian Cancer | 590 | 2032-05-01 |